$RARE

$15.50▲ -5.0% YTD

14 SEC 13D/G filings tracked · Last updated Nov 3, 2026

Filing History

RARE ▼ -5.0% - Ultragenyx Pharmaceutical Inc.

CP $15.50▲ -5.0%Nov 3, 2026 · ThinkSabio Blog

$RARE - Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027…

SEC 13D/G

RARE - Ultragenyx Pharmaceutical Inc. - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks Simplified

$16.05▼ -32.02%Oct 30, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE Ultragenyx Pharmaceutical Inc. : $16.05 Sector: Healthcare…

News

RARE ▲ +4.1% - Ultragenyx Pharmaceutical Inc.

CP $16.75▲ +4.1%Oct 27, 2026 · ThinkSabio Blog

$RARE - Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update…

SEC 13D/G

RARE - Ultragenyx Pharmaceutical Inc. - SEC Filing Update (20-OCT-2026) | ThinkSabio - Stocks Simplified

$16.00▼ -32.23%Oct 20, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE Ultragenyx Pharmaceutical Inc. : $16.00 Sector: Healthcare…

News

RARE ▲ +2.1% - Ultragenyx Pharmaceutical Inc.

CP $15.23▲ +2.1%Oct 14, 2026 · ThinkSabio Blog

$RARE - Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million…

News

RARE ▲ +12.2% - Ultragenyx Pharmaceutical Inc.

CP $14.50▲ +12.2%Sep 17, 2026 · ThinkSabio Blog

$RARE - Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)…

News

RARE ▼ -42.8% - Ultragenyx Pharmaceutical Inc.

CP $14.75▲ -42.8%Sep 2, 2026 · ThinkSabio Blog

$RARE vol down…

News

RARE ▼ -41.8% - Ultragenyx Pharmaceutical Inc.

CP $15.00▲ -41.8%Sep 2, 2026 · ThinkSabio Blog

$RARE - Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome…

News

RARE ▲ +2.0% - Ultragenyx Pharmaceutical Inc.

CP $25.73▲ +2.0%Sep 1, 2026 · ThinkSabio Blog

$RARE - Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also…

SEC 13D/G

RARE - Ultragenyx Pharmaceutical Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified

$26.59▲ 12.62%Aug 14, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE Ultragenyx Pharmaceutical Inc. : $26.59 Sector: Healthcare…

SEC 13D/G

RARE - Ultragenyx Pharmaceutical Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks Simplified

$26.69▲ 13.05%Aug 13, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE Ultragenyx Pharmaceutical Inc. : $26.69 Sector: Healthcare…

SEC 13D/G

$RARE SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks Simplified

$24.74▲ 4.79%Jul 31, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE : $24.74 Sector: Healthcare | YTD: 🔼+ 4.79% The SEC disclo…

SEC 13D/G

$RARE SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks Simplified

$25.03▲ 6.01%Jul 31, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE : $25.03 Sector: Healthcare | YTD: 🔼+ 6.01% The SEC disclo…

SEC 13D/G

$RARE SEC Filing Update (30-JUL-2026) | ThinkSabio - Stocks Simplified

$25.06▲ 6.14%Jul 30, 2026 · ThinkSabio Blog

$RARE SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #RARE : $25.06 Sector: Healthcare | YTD: 🔼+ 6.14% The SEC disclo…